Amgen (NASDAQ:AMGN) saw its share price trade relatively negative in the recent trading session. The share price was last updated to $149.42 with a loss of -1.23 points or -0.82%. The net money flow was $5.84 million and the up/down ratio was 1.08. Approximately $80.42 million was the inflow in upticks and $74.58 million was the outflow in downticks. On a weekly measure, the shares have seen a price change of -0.13%.The shares witnessed a block transaction with a net money flow of $-0.54 million. The total money in uptick was $3.49 million and in downtick was $4.03 million with the up/down ratio reaching 0.87.
The stock has recorded a 20-day Moving Average of 3.73% and the 50-Day Moving Average is 4.18%. The company shares have dropped 6.83% in the past 52 Weeks. On July 31, 2015 The shares registered one year high of $181.81 and one year low was seen on September 28, 2015 at $130.09. The 50-day moving average is $154.46 and the 200 day moving average is recorded at $153.51. S&P 500 has rallied 1.93% during the last 52-weeks.
Amgen (NASDAQ:AMGN): The stock opened at $151.14 on Tuesday but the bulls could not build on the opening and the stock topped out at $151.47 for the day. The stock traded down to $148.50 during the day, due to lack of any buying support eventually closed down at $149.42 with a loss of -0.82% for the day. The stock had closed at $150.65 on the previous day. The total traded volume was 2,622,241 shares.
Currently the company Insiders own 0.2% of Amgen shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -25.24% . Institutional Investors own 83.17% of Amgen shares. During last six month period, the net percent change held by insiders has seen a change of -25.24%. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Balachandran Madhavan, officer (EVP, Operations) of Amgen Inc, had unloaded 30,000 shares at an average price of $154.12 in a transaction dated on May 4, 2016. The total value of the transaction was worth $4,623,600.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.